Marvel Biosciences Corp.: Marvel Biosciences Closes Second Tranche of Private Placement

Calgary, Alberta--(Newsfile Corp. - August 9, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased

Related Keywords

United States ,Canada ,Canadian ,Kostenloser Wertpapierhandel ,Mark Williams ,Company The Units ,Canaccord Genuity Corp ,Research Capital Corporation ,Marvel Biosciences Corp ,Marvel Biotechnology Inc ,Companya Common Share ,Virtus Advisory Group ,Raymond James Ltd ,Alberta Newsfile Corp ,Venture Exchange ,Company Or Marvel ,Regulation Services Provider ,Each Unit ,Common Share ,Each Warrant ,Accelerated Expiry Date ,Accelerated Expiry ,Minority Security Holders ,Special Transactions ,Capital Corporation ,Raymond James ,Canaccord Genuity ,United States Securities Act ,Chief Executive Officer ,Chief Science ,Marvel ,Iosciences ,Orp ,Loses ,Second ,Tranche ,Private ,Placement ,